Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...

RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...